

Remedy Pharmaceuticals Announces Traumatic Brain Injury Drug Study

Breakthrough multi-million dollar study funded by the U.S. Department of Defense expected to begin later this year

New York, NY, USA - July 1, 2011 – Remedy Pharmaceuticals, Inc. today announced an agreement with the INTRuST Consortium to conduct a Phase 2 clinical trial of its lead candidate RP-1127 for the treatment of moderate and severe acute Traumatic Brain Injury (TBI).

The randomized, double-blind, placebo-controlled clinical trial will be conducted by the INTRuST Consortium, a group of clinical study centers in the United States funded by a U.S. Department of Defense award to advance treatments and medical research in PTSD and traumatic brain injury. This public-private collaboration will study RP-1127 under Remedy's Investigational New Drug Application (IND) filed with the Food and Drug Administration (FDA). The trial will take place in the United States and is designed to enroll approximately 100 moderate and severe TBI patients.

The study's Principal Investigator is Howard Eisenberg, MD, R.K. Thompson Professor and Chairman, Department of Neurosurgery, University of Maryland School of Medicine. Dr. Eisenberg has been Principal Investigator on numerous high profile TBI studies.

The INTRuST trial leader is Lawrence F. Marshall, MD, an internationally renowned research expert in traumatic head injury and creator of the Marshall CT classification, the *de facto* standard in traumatic brain injury for determining prognosis.

"There are currently no approved pharmaceutical therapies for TBI, and compelling preclinical and clinical studies of RP-1127 in multiple indications give us great hope that RP-1127 will address this critical need," said Sven Jacobson, Chief Executive Officer of Remedy.

About RP-1127

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NC_{Ca-ATP} channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

About Remedy Pharmaceuticals

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: info@remedypharmaceuticals.com